Evonik showcases innovation through unique products and new market concept at NYSCC Suppliers’ Day 2019

Affirming its commitment to specialty active ingredients, Evonik will showcase new product solutions that are in sync with present market trends.

Consumer interest in sustainable, plant-derived active ingredients continues to grow. During Suppliers’ Day, Evonik will showcase the first widely available product leveraging its Advanced Botanicals technology platform. NeoPlanta^® Withania offers a biotechnologically optimized extract of traditional Ayurvedic herb Withania somnifera, also known as Indian Ginseng. The product offers protection against premature skin aging caused by stress and environmental factors, an acute need by today’s urban-bound consumers. In addition to enabling phytochemical optimization, Evonik’s controlled cultivation process ensures reliability in yields and quality while removing adverse ecological impacts.

Blue light protection has emerged as an unmet need by today’s technologically-immersed consumer. Evonik’s new tetrapeptide, TEGO^® Pep-UP, has been demonstrated to protect the skin against damaging blue light emitted from mobile devices and computer screens. The CFDA-approved product uses biomimicry to deliver several additional visual benefits, most notably the appearance of a more defined and less sagging facial contour.

During Suppliers’ Day, Evonik Dr. Straetmans will present new products and inspirations that highlight Evonik’s ongoing leadership in sustainable chemistry.

During the event, Evonik will showcase new extensions of the dermofeel^® antioxidants range for use in certified natural cosmetics:

• dermofeel^® TocoBalance is a rapeseed-based natural antioxidant with a balanced content of mixed tocopheroles from non-GMO sources. It offers effective protection of oxidizable ingredients with the added benefit of antioxidative activity for the skin.

• dermofeel^® TocoSkin is a sunflower-based antioxidant from non-GMO sources with a high content of alpha-Tocopherol (vitamin E). It also prevents the skin from damage caused by free radicals.

Traditional preservatives are being subject to closer scrutiny. As a result, some standard preserving systems are losing public acceptance, facing greater legal restriction, or being prohibited outright. For formulators, this poses a challenge. Those seeking alternative preservation solutions, including for natural cosmetics, can explore Evonik’s dermosoft^® range of multifunctional additives. Chemists seeking more established, economic preservation systems can explore Evonik’s Verstatil^® products. Both solutions will be featured at the show.

To facilitate finished product development, Evonik is presenting a new market concept and new web-based tools that can enable formulators to achieve success more quickly.

Facial masks are a rapidly growing segment of the skin care market, in part because of their aspirational and ritualistic qualities. As this segment matures, consumers have been demanding that masks also deliver tangible skin-improvement benefits. Treatment Masques embrace a differentiated skin treatment experience by combining a ritualistic ethos with scientifically-driven beauty. Through careful study of this segment, Evonik has prepared a collection of facial treatment mask formulations that can help inspire brands seeking to benefit from the momentum of this product category.

Come experience unique sensorial formats tailored to the needs of different facial areas and proven cosmetic actives at Evonik’s booth #1111 during the event.

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2018, the enterprise generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.6 billion.

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.